Biocept Publishes on Mechanics and Performance of its Onco CEE™ Platform for Circulating Tumor Cells (CTCs) in Cancer Patients San Diego, California: – Biocept, Inc., a privately-held CLIA-certified laboratory testing company, focused on the detection and analysis of circulating tumor cells (CTCs)
Announces distribution of nearly 12,000 specimen collection kits to clients and has current availability of approximately 18,000 kits for immediate distribution Expects Company-developed collection kits to be available later this quarter SAN DIEGO , Aug. 3, 2020 /PRNewswire/ -- Biocept, Inc .
Intellectual property estate now includes 25 issued patents for Biocept's highly sensitive methods for detecting cancer biomarkers in circulating tumor DNA (ctDNA) and on circulating tumor cells (CTCs) SAN DIEGO , Feb. 5, 2018 /PRNewswire/ -- Biocept, Inc.
Further expands global patent estate for capturing and detecting rare cells of interest, including CTCs, to aid in the treatment of patients with cancer SAN DIEGO , Nov. 9, 2020 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of molecular diagnostic assays, products
SAN DIEGO --(BUSINESS WIRE)--Jun. 15, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it has received more than 420,000 samples for SARS-CoV-2 testing since launching this service in June 2020 .
Expands company’s patent portfolio in pursuit of worldwide intellectual property protection for proprietary technology that detects biomarkers in tissue, blood, and cerebrospinal fluid SAN DIEGO --(BUSINESS WIRE)--Jul. 6, 2021-- Biocept, Inc . (NASDAQ: BIOC), a leading provider of molecular
New patents further expand the Company's intellectual property estate for capturing and detecting rare cells of interest, including circulating tumor cells (CTCs), to aid in the management of patients with cancer Biocept now has 36 issued patents globally covering its novel liquid biopsy
To be a shareholder of record, investors are advised to own Biocept stock by 4:00 PM ET, Thursday, July 19, 2018 to account for T+2 settlement timing Record date established as Monday, July 23, 2018 SAN DIEGO , July 19, 2018 /PRNewswire/ -- Biocept, Inc.
Billable sample volume increases by more than 30% for third consecutive quarter reaching full-year 2015 total of 1,8242015 revenues grow more than three-foldConference call begins at 4:30 p.m. Eastern time today
Billable sample volume increases 280% year-over-year and marks the fourth consecutive quarter of double-digit sequential growthConference call begins at 4:30 p.m. Eastern time today
